Balyasny Asset Management
FTH

Balyasny Asset Management’s Faeth Therapeutics FTH Stock Holding History

Balyasny Asset Management’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$511K Buy
+16,205
New +$324K ﹤0.01% 2359
2021
Q2 		– Sell
-1,380
Closed -$401K – 2317
2021
Q1 		$401K Buy
+1,380
New +$462K ﹤0.01% 1451

Other funds holding FTH

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Balyasny Asset Management's FTH Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Faeth Therapeutics (FTH) in Q1 2026: 16,205 shares worth $511K. The stake represents ﹤0.01% of the portfolio and ranks #2359 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in FTH as recently as Q1 2021.

Balyasny Asset Management first reported a position in FTH in Q1 2021 and has held it in 2 quarters since. 30 funds tracked by Wall St. Rank hold FTH as of Q1 2026.

  • Balyasny Asset Management held 16,205 shares of Faeth Therapeutics worth $511K as of Q1 2026.
  • Faeth Therapeutics was a new Balyasny Asset Management position in Q1 2026.
  • Faeth Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2359 holding.
  • Balyasny Asset Management first reported a position in Faeth Therapeutics in Q1 2021 and has held it in 2 quarters since.
  • 30 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.